| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 4 | Page : 167-171 |
|
|
Anticoagulant status under COVID-19: The potential pathophysiological mechanism
Basheer Abdullah Marzoog
Medical School Student at National Research Mordovia State University, Saransk, Russia
Correspondence Address:
Dr. Basheer Abdullah Marzoog
Mordovia Republic, Saransk, Bolshevitskaya Street, 31
Russia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joah.joah_154_21
|
|
|
Coronavirus disease 19 (COVID-19) is a systematic multitropic disease. Sustaining blood homeostasis is a mission of multiple factors includes procoagulant and anticoagulant systems. Subsequently, maintaining a precise equilibrium between these antagonists' systems is crucial to prevent hemostasis. Frequently, during severe forms of COVID-19 patients, studies reported a discrepancy between the procoagulant and anticoagulant that usually results in fatal outcomes through multiorgan ischemia by thrombotic events. The proper interpreting of the anticoagulant status changes in COVID-19 patients is sufficient for effective and safe anticoagulant treatment. Our postulation is the first to address the pathophysiology of anticoagulant status under COVID-19.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
